This article has been updated from a previous version to include clarifying information from Veracyte about the developers of the gene signature.
NEW YORK – Veracyte said on Thursday that it has signed an exclusive licensing agreement with Yale University for a genomic test to predict disease progression in patients with idiopathic pulmonary fibrosis (IPF).